Please login to the form below

Not currently logged in
Email:
Password:

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

Novartis  

Novartis's recently approved biosimilar of Amgen's cancer side effects drug has been blocked from sale in the US.

An appeals court is stopping the sale of the Neupogen biosimilar - a drug used to prevent infections in cancer patients - after rejecting a lower court decision that denied an injunction request from Amgen, the original drug's manufacturer. 

The US Court of Appeals for the Federal Circuit is now saying that the injunction could take effect while Amgen's appeal is pending - oral arguments on the appeal have been set for June 3.

In a statement, Amgen said it is pleased with the ruling while Novartis said it looks forward to a “prompt resolution” of the appeal so it can launch its drug “in the near future”.

Novartis' drug has been patented under the name Zarxio and contains the same active ingredient as Neupogen - a product that makes around $1.2bn a year.

When the drug is launched it will become the first biosimilar to be sold in the US. In 2010, President Barack Obama's healthcare reforms allowed the use of biosimilars in the country - drugs that are bioequivalent to original medicines, but which require some R&D as they involve creating living tissue.

Biosimilars have been on the market since 2006 in Europe but the US is much further behind in its regulatory pathway. 

The global biosimilar market is expected to make large savings to payers for biologics, with each product expected to be around 20-50% cheaper that the original drug. Novartis has not yet disclosed the intended US price for Zarxio.

The FDA approved Zarxio in March for the same five conditions for which Neupogen is used among cancer patients undergoing various treatments.

Article by
Ben Adams

8th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics